In patients recovering from coronavirus disease 2019 (COVID-19), specific T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been detected [1]. These responses targeted not only the spike (S) protein but also the membrane (M), nucleocapsid (N), and other open reading frames (ORFs) [2]. A licensed inactivated COVID-19 vaccine in China, BBIBP-CorV, induced good humoral responses [3]. However, whether virus-specific T cell immunity could be induced by BBIBP-CorV has not yet been clarified. Given that recent studies have demonstrated that mRNA (BNT162b2, mRNA-1273) and viral vector vaccines elicit strong T cell responses as well as neutralizing Abs against SARS-CoV-2 [4], we conducted a study to evaluate the T-cell response to SARS-CoV-2 before and after receiving BBIBP-CorV.
The study was approved by the Institutional Review Board of the China CDC. All vaccinees provided written informed consent. We collected blood samples from 10 healthy individuals before and after vaccination (median age, 35.5 years; range, 23–51; 3 males and 7 females) who received BBIBP-CorV containing 4 μg of total protein on days 0 and 21. Postvaccination blood was collected 12 weeks after the second dose. We performed IFN-y ELISpot assays on PBMCs to quantify the frequency of virus-specific T cells (details are provided in the Supplementary Appendix, available with the full text of this letter). A significant increase in IFN-γ spot-forming units (SFU) per million peripheral blood mononuclear cells (PBMCs) was observed against the S, N and E peptide pools of SARS-CoV-2 after vaccination (Fig. 1A–C). Nevertheless, the increase was not statistically significant for the M peptide pools, although the increase in IFN-γ SFU per million PBMCs was observed in six out of the 10 study participants (Fig. 1D). Given the presence of a certain degree of homology in the amino acid sequence of epitope peptides between SARS-CoV-2 and endemic HCoVs, preexisting SARS-CoV-2-reactive T cells or cross-reactivity with HCoVs might be detected in certain individuals; [5] this was observed in the significant SFU background in the prevaccination samples. We also tested postvaccination serum samples for IgG antibodies against the S protein (details on the laboratory assays are provided in the Supplementary Appendix). All study participants had detectable IgG antibodies with a median titer of 1:80 (range: 1:10 to 1:160). There was no significant correlation between the IgG antibody titer and IFN-γSFU against the S protein (Spearman’s correlation coefficient ρ = −0.53, P = 0.11).
Our findings demonstrate that specific T cell responses to multiple structural proteins (S, N, and E proteins) of SARS-CoV-2 were elicited in BBIBP-CorV recipients. This suggests that inactivated vaccines against SARS-CoV-2 may elicit T-cell responses in addition to humoral responses, and cellular responses may play a role in the protection offered by inactivated vaccines. Our findings also suggest that there is likely no association between vaccine-induced T cell responses and humoral immunity. The limitations of this study were the limited number of study participants and lack of a phenotypical characterization of the SARS-CoV-2 T-cell response. Further experiments will be very helpful for characterizing the T-cell subsets and their responses to SARS-CoV-2 in a larger sample of participants. It is important to determine the immune correlates of protection against SARS-CoV-2 infection.
References
Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529–36. John Wherry. 2020
Cassaniti I, Percivalle E, Bergami F, A Piralla, G Comolli, R Bruno, et al. SARS-CoV-2 specific T cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex-vivo ELISpot assay. Clin Microbiol Infect. 2021. S1198-743X (21)00145-2.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2020;21:39–51.
Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178–81.
Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270–4.
Acknowledgements
We thank all vaccine recipients for providing blood and PBMC samples. This work was supported by grants from the National Natural Science Foundation of China (82041041, 82061138008).
Author information
Authors and Affiliations
Contributions
WJT and YD conceived of the study. YD and RY performed the experiment; YD, YL, and WJT analyzed the data; WJT and YL drafted the manuscript. All authors reviewed and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Deng, Y., Li, Y., Yang, R. et al. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients. Cell Mol Immunol 18, 2040–2041 (2021). https://doi.org/10.1038/s41423-021-00730-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-021-00730-8
This article is cited by
-
Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds
Signal Transduction and Targeted Therapy (2023)
-
Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination
Scientific Reports (2023)
-
Adaptive immune responses and cytokine immune profiles in humans following prime and boost vaccination with the SARS-CoV-2 CoronaVac vaccine
Virology Journal (2022)
-
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern
Cell Research (2022)
-
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Cell Discovery (2022)